Preeclampsia is a dreadful disease with significant morbidity and mortality. Despite decades of research, we still need a proper diagnostic test or therapeutic option to treat this disorder. The proposed study will determine the diagnostic value of PBMC-secreted sFlt1 and determine the molecular mechanisms involved in its secretion. The molecular mechanisms can be novel therapeutic targets to treat this disorder.
Study Type
OBSERVATIONAL
Enrollment
500
sFLT1 levels
sFLT1 levels in preeclampsia should be higher than normal pregnancy.
Time frame: Outcome will be measured at 12 weeks, 24 weeks and 36 weeks of pregnancy.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.